EUVIMEDEUVIMED entdecken
Crossref

Establishment and Evaluation of Human iPS Cell‐Derived Myeloid Cell Lines Susceptible to SARS‐CoV‐2

Takayuki Hishiki iD, Yuka Yoshimura, Rieko Suzuki, Ami Murakami, Yua Saito, Naomi Tanga, Jun Shimizu, Koichi Watashi, Tomohiko Takasaki, Kazuo Miyazaki

Microbiology and Immunology · 2026-05 · 70 (5) · 285-289

DOI: 10.1111/1348-0421.70053 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Microbiology and Immunology, online erschienen am 10.03.2026. Verfasst von Takayuki Hishiki und 9 weiteren Autor:innen. Beteiligte Einrichtung: Kanagawa Prefectural Institute of Public Health, Chigasaki, Kanagawa, Japan. Hauptthemen laut MEDLINE: SARS-CoV-2, Myeloid Cells, Induced Pluripotent Stem Cells. Die Arbeit nennt 24 Literaturangaben. Gefördert von: METI Monozukuri R&D Support, JSPS KAKENHI, Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

To accelerate the development of antiviral drugs, we generated human iPS cell‐derived myeloid cell lines, which were susceptible to SARS‐CoV‐2 infection. Viral isolation using clinical specimens showed that some novel cell lines performed better than VeroE6/TMPRSS2. In addition, viral genome mutations that occurred during viral passaging did not happen in VeroE6/TMPRSS2 but accumulated in these cell lines, and those mutations were reported in clinical specimens. Furthermore, the antiviral efficacy of remdesivir differed among the cell types. These findings suggest that the novel myeloid cell lines may serve as a useful platform for virus isolation and the evaluation of antiviral responses.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SARS-CoV-2Myeloid CellsInduced Pluripotent Stem CellsHumansCell LineAntiviral AgentsAnimalsChlorocebus aethiopsCOVID-19Vero CellsGenome, ViralAdenosine MonophosphateAlanineMutation

Stichwörter der Autor:innen

SARS‐CoV‐2antiviral activityhuman iPS cell‐derived myeloid cell linesviral genomeviral isolation

Substanzen

Antiviral AgentsremdesivirAdenosine MonophosphateAlanine

Autor:innen und Institutionen

  • Kanagawa Prefectural Institute of Public Health, Chigasaki, Kanagawa, Japan.
  • Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Shinjuku-ku, Tokyo, Japan.
  • Department of Drug Development, National Institute of Infectious Diseases, Japan Institute for Health Security, Shinjuku-ku, Tokyo, Japan.
  • MiCAN Technologies Inc., Kyoto, Japan.

ORCID-Profile: Takayuki Hishiki

Förderung

  • METI Monozukuri R&D Support
  • JSPS KAKENHI
  • Japan Society for the Promotion of Science

Zitieren

APA

Hishiki, T., Yoshimura, Y., Suzuki, R., Murakami, A., Saito, Y., Tanga, N., Shimizu, J., Watashi, K., Takasaki, T., & Miyazaki, K. (2026). Establishment and Evaluation of Human iPS Cell‐Derived Myeloid Cell Lines Susceptible to SARS‐CoV‐2. Microbiology and Immunology, 70(5), 285-289. https://doi.org/10.1111/1348-0421.70053

Vancouver

Hishiki T, Yoshimura Y, Suzuki R, Murakami A, Saito Y, Tanga N, et al. Establishment and Evaluation of Human iPS Cell‐Derived Myeloid Cell Lines Susceptible to SARS‐CoV‐2. Microbiology and Immunology. 2026;70(5):285-289. doi:10.1111/1348-0421.70053

BibTeX
@article{Hishiki2026,
  author = {Hishiki, Takayuki and Yoshimura, Yuka and Suzuki, Rieko and Murakami, Ami and Saito, Yua and Tanga, Naomi and Shimizu, Jun and Watashi, Koichi and Takasaki, Tomohiko and Miyazaki, Kazuo},
  title = {Establishment and Evaluation of Human iPS Cell‐Derived Myeloid Cell Lines Susceptible to SARS‐CoV‐2},
  journal = {Microbiology and Immunology},
  year = {2026},
  volume = {70},
  number = {5},
  pages = {285--289},
  doi = {10.1111/1348-0421.70053}
}
Kostenlos starten →